Oculis Holding AG Ordinary shares

Yahoo Finance • 9 days ago

Pre-Market Earnings Report for November 18, 2025 : HD, PDD, MDT, BIDU, ESLT, AS, BZ, JHX, BRBR, ENR, WB, OCSL

The following companies are expected to report earnings prior to market open on 11/18/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Home Depot, Inc. (HD)is reporting for the quarter ending October 31... Full story

Yahoo Finance • 16 days ago

Oculis Holding GAAP EPS of CHF -0.32

* Oculis Holding press release [https://seekingalpha.com/pr/20301359-oculis-reports-q3-2025-financial-results-and-provides-company-update] (OCS [https://seekingalpha.com/symbol/OCS]): Q3 GAAP EPS of CHF -0.32. * Operating income of CHF... Full story

Yahoo Finance • 16 days ago

Oculis Reports Q3 2025 Financial Results and Provides Company Update

ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) andNon-arteritic Anterior Ischemic Optic Neuropathy... Full story

Yahoo Finance • 16 days ago

Oculis birtir uppgjör fyrir þriðja ársfjórðung 2025 og kynnir áfanga í rekstri félagsins

ZUG, Sviss, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Oculis hraðar þróunaráætlun sinni í kjölfar árangursríks fundar með Matvæla- og lyfjastofnun Bandaríkjanna (FDA), með PIONEER-rannsóknaráætluninni á Privosegtor sem meðferð við bráðri sjónta... Full story

Yahoo Finance • 21 days ago

Oculis to Participate in Upcoming November Investor Conferences

ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophtha... Full story

Yahoo Finance • 27 days ago

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs... Full story

Yahoo Finance • 27 days ago

Oculis greinir frá umframeftirspurn í 110 milljóna USD fjármögnun sem er ætlað til að hraða klínískri þróun Privosegtor

ZUG, Sviss, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) („Oculis“ eða „félagið“), alþjóðlegt líftæknilyfjafyrirtæki með áherslu á á nýsköpun til að meðhöndla augnsjúkdóma og augntaugasjúkdóma og mæta veru... Full story

Yahoo Finance • last month

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significan... Full story

Yahoo Finance • 2 months ago

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program, which includes mu... Full story

Yahoo Finance • 2 months ago

Oculis hrindir af stað skráningarrannsóknum á Privosegtor við bráðri sjóntaugabólgu, sem gæti orðið fyrsta taugaverndandi meðferð sinnar tegundar

ZUG, Sviss, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Árangursríkur fundur með Matvæla- og lyfjastofnun Bandaríkjanna (FDA) skapar möguleika á að hefja skráningarrannsóknir á Privosegtor sem meðferð við bráðri sjóntaugabólgu (e. Acute Optic Neur... Full story

Yahoo Finance • 2 months ago

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

ZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial... Full story

Yahoo Finance • 3 months ago

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet me... Full story

Yahoo Finance • 3 months ago

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 eye drops in diabetic macular edema (DM... Full story

Yahoo Finance • 3 months ago

Citi initiates Lumentum coverage with Buy, citing AI optics leadership

[Lumentum Corporate Headquarters in San Jose, California, USA] JHVEPhoto Citi initiated coverage on Lumentum Holdings (NASDAQ:LITE [https://seekingalpha.com/symbol/LITE]) with a Buy rating, expecting more upside in the stock, beyond its c... Full story

Yahoo Finance • 3 months ago

Oculis to Participate in Upcoming September Investor Conferences

ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovative solutions for ophthalmic and neuro-ophthalmic diseases with s... Full story

Yahoo Finance • 3 months ago

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors

Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple programs in neuro-ophthalmologySeba... Full story

Yahoo Finance • 3 months ago

Oculis Holding stock price target raised to $33 from $32 at H.C. Wainwright

Investing.com - H.C. Wainwright raised its price target on Oculis Holding AG (NASDAQ:OCS) to $33.00 from $32.00 on Friday, while maintaining a Buy rating on the stock. Currently trading at $17.80, the stock sits within a broader analyst ta... Full story

Yahoo Finance • 3 months ago

Oculis Reports Q2 2025 Financial Results and Provides Company Update

ZUG, Switzerland, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Focused execution in Q2 2025 to advance Oculis’ pipeline in ophthalmology and neuro-ophthalmology. OCS-01: Both pivotal Ph3 DIAMOND trials are fully enrolled, with topline results exp... Full story

Yahoo Finance • 3 months ago

Oculis birtir uppgjör fyrir annan ársfjórðung 2025 og kynnir áfanga í rekstri félagsins

ZUG, Sviss, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Á öðrum ársfjórðungi 2025 vann Oculis markvisst að áframhaldandi þróun lyfja á sviði augn- og augntaugasjúkdóma. OCS-01: Innritun sjúklinga í báðar DIAMOND fasa 3 lykilrannsóknirnar er loki... Full story

Yahoo Finance • 3 months ago

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant u... Full story